Cresemba (Isavuconazonium Sulfate) Patent Expiration, LOE Window & CMS Spending

Cresemba (Isavuconazonium Sulfate) by Astellas Pharma: FDA Orange Book core substance LOE 2026-04-30 (last listed 2031-06-08), 0 AB generics, $157.2M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN207500 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2026-04-30
Last Listed Patent or Exclusivity Date2031-06-08
Orange Book Patents (*PED Extensions)6 patents (3 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$157.2M
2024 Medicare Part D Spend$123.0M
2024 Medicaid Spend$34.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.